Literature DB >> 1800701

Absorption of flurbiprofen through human buccal mucosa.

I Gonzalez-Younes1, J G Wagner, D A Gaines, J J Ferry, J M Hageman.   

Abstract

The absorption of flurbiprofen through human buccal mucosa was studied after 25 mL of a 2.5-mg/mL solution (pH 4) of the drug in a cosolvent mixture (ethanol 95%:glycerin:propylene glycol:0.3 M sodium acetate buffer, 10:40:30:20) was held and circulated in the mouth for 5 min in a "buccal absorption test." The results were compared with those obtained after oral administration of 25 mL of a solution (pH 7) of sodium flurbiprofen having the same concentration. Twelve subjects participated in the crossover study. After the buccal treatment, mean Cmax and Tmax values were 0.751 micrograms/mL and 41 min, respectively. Average Cmax and Tmax values after the oral treatment were 10.8 micrograms/mL and 32 min, respectively. Mean dose-corrected AUCs were 0.0854 and 0.811 (micrograms.h/mL)/mg for the buccal and the oral treatments, respectively. The absorption kinetics after the buccal treatment were evaluated using the Exact Loo-Riegelman Method (ELRM). Buccal plasma flurbiprofen concentration-time data for 11 subjects were very well fitted by reconstructed curves using ka and the lag-time obtained from ELRM analysis of the buccal data and the disposition parameters obtained from the oral data. These results strongly support the concept of intrasubject constancy of flurbiprofen disposition parameters. Analysis, by ELRM, of the plasma concentration-time data obtained after the buccal treatment indicated first-order absorption, with a mean ka value of 3.9 +/- 2.2 h-1. This value was significantly different (0.05 greater than p greater than 0.02) from the ka after oral treatment (7.89 +/- 5.2 h-1), obtained from the triexponential fitting of the oral plasma data.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1800701     DOI: 10.1002/jps.2600800903

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  6 in total

1.  Understanding the oral mucosal absorption and resulting clinical pharmacokinetics of asenapine.

Authors:  Jeremy A Bartlett; Kees van der Voort Maarschalk
Journal:  AAPS PharmSciTech       Date:  2012-08-31       Impact factor: 3.246

Review 2.  Clinical pharmacokinetics of flurbiprofen and its enantiomers.

Authors:  N M Davies
Journal:  Clin Pharmacokinet       Date:  1995-02       Impact factor: 6.447

3.  Determination of the Permeation and Penetration of Flurbiprofen into Cadaveric Human Pharynx Tissue.

Authors:  Rob Turner; Sean Robert Wevrett; Suzanne Edmunds; Marc B Brown; Robert Atkinson; Oluwajoba Adegoke; Anuradha Kulasekaran; Tim Shea
Journal:  Clin Pharmacol       Date:  2020-03-24

Review 4.  Locally Delivered Flurbiprofen 8.75 mg for Treatment and Prevention of Sore Throat: A Narrative Review of Clinical Studies.

Authors:  Ferdinandus de Looze; Adrian Shephard; Adam B Smith
Journal:  J Pain Res       Date:  2019-12-27       Impact factor: 3.133

5.  Penetration of Flurbiprofen from a Locally Applied Sore Throat Lozenge and Spray into Cadaveric Human Pharynx Tissue: A Novel ex vivo Model and Microautoradiography Method.

Authors:  Rob Turner; Sean Robert Wevrett; Suzanne Edmunds; Marc Brown; Anuradha Kulasekaran; Oluwajoba Adegoke; John Farrah
Journal:  Clin Pharmacol       Date:  2021-01-19

6.  Validation of an analytical method to quantify the permeation and penetration of flurbiprofen into human pharynx tissue.

Authors:  Rob Turner; Sean Robert Wevrett; Suzanne Edmunds; Marc Brown; Robert Atkinson; Tim Shea
Journal:  Biomed Chromatogr       Date:  2019-05-06       Impact factor: 1.902

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.